| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥89.3B | ¥84.2B | +6.0% |
| Operating Income | ¥20.1B | ¥15.6B | +29.5% |
| Ordinary Income | ¥20.1B | ¥15.4B | +30.8% |
| Net Income | ¥21.5B | ¥15.7B | +36.9% |
| ROE | 21.7% | 18.4% | - |
FY2026 Q3 consolidated results showed strong performance with revenue of ¥89.3B (YoY +6.0%), operating income of ¥20.1B (+29.5%), ordinary income of ¥20.1B (+30.8%), and net income of ¥21.5B (+36.9%). The company demonstrated significant profit expansion outpacing revenue growth, with operating margin expanding to 22.6% and net margin reaching 24.1%. The bottom-line growth was particularly robust, accelerating at nearly six times the rate of revenue growth, driven by operational leverage and favorable tax effects. Cash position strengthened materially to ¥33.5B, up 59.2% YoY, reflecting improved liquidity. The company operates as a single-segment business providing solutions to pharmacies, medical institutions, and nursing care facilities.
Revenue grew 6.0% YoY to ¥89.3B, reflecting steady demand expansion in the pharmacy and healthcare solutions market. The company serves a single integrated market of pharmacies, medical institutions, and nursing care facilities, with growth driven by increased adoption of its solution offerings and expansion of the existing customer base. Gross profit reached ¥50.8B with a margin of 57.0%, indicating strong pricing power and a favorable service-oriented business model. SG&A expenses totaled ¥30.7B, representing 34.4% of revenue, demonstrating effective operating leverage as the ratio improved from prior periods while supporting revenue growth.
Operating income surged 29.5% to ¥20.1B, substantially outpacing revenue growth and reflecting improved operational efficiency. The operating margin expanded to 22.6%, up significantly from the prior year, driven by gross margin stability and SG&A leverage. Ordinary income increased 30.8% to ¥20.1B, closely aligned with operating income, suggesting minimal non-operating impacts. Non-operating income and expenses largely offset at ¥0.4B each, with interest expense of ¥0.1B reflecting modest debt servicing costs.
Net income jumped 36.9% to ¥21.5B, exceeding ordinary income by ¥1.4B. This unusual dynamic reflects extraordinary income of ¥0.1B and a negative effective tax rate of approximately -6.9%, indicating significant tax benefits likely from deferred tax asset recognition or tax loss carryforwards reversal. While this tax effect boosted near-term earnings, it represents a non-recurring factor that may not persist in future periods. Basic EPS reached ¥189.36, up 33.1% YoY, slightly below net income growth due to share count adjustments.
This represents a revenue up/profit up pattern with accelerated profit growth driven by operational leverage and temporary tax benefits.
[Profitability] ROE of 21.7% demonstrates strong return generation, substantially exceeding the company's cost of capital. Operating margin of 22.6% reflects the high-value nature of software and solution services, with gross margin of 57.0% indicating strong pricing power in the healthcare IT market. Net profit margin reached 24.1%, elevated by favorable tax effects. [Cash Quality] Cash and deposits of ¥33.5B provide 3.35x coverage of short-term debt, indicating robust liquidity. The cash position increased 59.2% YoY, strengthening the balance sheet buffer. [Investment Efficiency] Asset turnover of 0.60 reflects the intangible asset-intensive nature of the business, with software comprising ¥39.1B or 26.3% of total assets. [Financial Health] Equity ratio of 66.6% demonstrates conservative capitalization with low leverage risk. Current ratio of 210.5% indicates strong short-term liquidity, though short-term liabilities represent 53.8% of total liabilities, warranting attention to refinancing continuity. Debt-to-equity ratio of 0.19 confirms minimal leverage, with interest-bearing debt totaling ¥18.6B against equity of ¥99.1B.
Cash and deposits increased ¥12.5B YoY to ¥33.5B, representing a 59.2% expansion that significantly strengthened liquidity positioning. This substantial cash accumulation occurred alongside operating profit growth of 29.5%, suggesting strong operating cash generation supported earnings expansion. Working capital movements show accounts receivable at ¥37.9B, representing 42.4% of revenue on an annualized basis, which translates to approximately 155 days sales outstanding, indicating extended collection cycles typical of institutional healthcare customers but warranting monitoring for collection risk. Long-term borrowings increased dramatically from ¥0.6B to ¥8.6B, a ¥8.0B addition suggesting strategic financing to support growth initiatives or balance sheet optimization. Treasury stock increased to -¥4.3B from near-zero, reflecting share repurchase activity that returned capital to shareholders. Retained earnings grew ¥18.1B to ¥56.6B, with the majority of net income retained for reinvestment. The combination of strong cash accumulation, modest debt addition, and capital returns indicates balanced financial management with adequate liquidity coverage at 3.35x short-term obligations.
Ordinary income of ¥20.1B versus operating income of ¥20.1B shows negligible non-operating net contribution, indicating earnings are predominantly driven by core operations. Non-operating income and expenses each totaled ¥0.4B, effectively offsetting and contributing minimally to earnings. Interest expense of ¥0.1B represents modest financing costs relative to the debt outstanding. The primary earnings quality concern stems from the gap between ordinary income of ¥20.1B and net income of ¥21.5B, with the ¥1.4B difference driven by an effective tax rate of -6.9%. This negative tax rate reflects non-cash tax benefits, likely from deferred tax asset recognition, which enhances reported earnings but does not represent sustainable operating performance or cash generation. While extraordinary items were minimal at ¥0.1B in gains, the tax effect represents approximately 6.5% of net income and warrants classification as a non-recurring boost. The underlying operating performance remains strong, but investors should normalize for the tax benefit when assessing sustainable earning power. Absent detailed operating cash flow disclosure, the extended accounts receivable cycle of 155 days suggests potential timing differences between revenue recognition and cash collection, though the substantial cash balance growth provides assurance of fundamental cash generation quality.
Full-year guidance projects revenue of ¥123.0B (+9.8% YoY), operating income of ¥24.5B (+25.4%), and ordinary income of ¥24.0B (+23.7%). Q3 cumulative progress rates stand at 72.6% for revenue, 82.2% for operating income, and 83.8% for ordinary income. Operating and ordinary income are tracking approximately 32-34 percentage points ahead of the standard 50% mid-year benchmark, indicating stronger-than-seasonal first-half performance. This front-loaded earnings profile suggests either accelerated project deliveries, seasonal business mix favoring H1, or conservative full-year guidance. Given the 82-84% progress rate through Q3, the company would need to generate only ¥4.4B in operating income in Q4 to meet guidance, compared to Q3 quarterly operating income of ¥20.1B for nine months, implying approximately ¥6.7B quarterly average. This suggests the guidance may prove conservative, though management may be anticipating typical Q4 seasonality or one-time factors. Annual dividend forecast of ¥36.00 per share implies a payout ratio of approximately 15.2% based on the EPS forecast of ¥236.79, maintaining a conservative capital distribution policy that prioritizes reinvestment and balance sheet strength.
Annual dividend forecast of ¥36.00 represents the company's distribution plan, with interim dividend of ¥9.00 and year-end dividend expected at ¥27.00. Based on forecast EPS of ¥236.79, the payout ratio stands at 15.2%, reflecting a highly conservative dividend policy that retains the vast majority of earnings for reinvestment. This low payout ratio provides substantial headroom for dividend sustainability and potential increases, supported by strong cash generation and low leverage. The company executed share repurchases during the period, with treasury stock increasing to ¥4.3B from near-zero in the prior year, representing meaningful capital return supplementing dividends. While specific repurchase amounts are not itemized, the treasury stock increase demonstrates active shareholder return alongside dividend payments. Combined, the total return ratio incorporating both dividends and buybacks would approximate 20-25% of earnings, remaining conservative relative to the strong cash position and low leverage. The capital allocation strategy prioritizes reinvestment in growth initiatives, particularly software development and intangible assets that comprise 31% of total assets, while maintaining flexibility for opportunistic returns.
Single-segment concentration in pharmacy and healthcare solutions creates customer base risk, as regulatory changes, healthcare reimbursement reforms, or technology disruption in the Japanese medical system could materially impact demand. The company's entire revenue base depends on the pharmacy, medical, and nursing care sectors, limiting diversification and exposing results to sector-specific headwinds. Software and intangible assets totaling ¥46.3B represent 31.1% of total assets, exceeding typical concentration thresholds and creating impairment risk if technology becomes obsolete, customer adoption slows, or competitive pressures intensify. A material impairment charge would directly impact equity and profitability. Accounts receivable of ¥37.9B with estimated days sales outstanding of 155 days indicates extended collection cycles that expose the company to customer credit risk and working capital pressure. If major institutional customers face financial stress or payment delays extend further, cash conversion could deteriorate materially despite strong reported earnings, particularly given the high short-term liability proportion requiring refinancing continuity.
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates strong competitive positioning within the IT and Telecom sector serving healthcare markets. Profitability metrics substantially exceed industry norms: ROE of 21.7% compares favorably to the industry median of 8.3%, placing the company in the top quartile for return generation. Operating margin of 22.6% significantly outperforms the industry median of 8.2%, reflecting superior operational efficiency and the high-margin nature of its healthcare solution offerings. Net profit margin of 24.1% stands well above the industry median of 6.0%, though elevated by temporary tax benefits, the underlying operating margin still demonstrates premium positioning. Financial health indicators show conservative capitalization: equity ratio of 66.6% exceeds the industry median of 59.2%, indicating lower leverage risk than peers. Current ratio of 210.5% compares favorably to the industry median of 2.15x, though this is influenced by the company's minimal inventory business model. Revenue growth of 6.0% trails the industry median of 10.4%, suggesting more mature market positioning or conservative market share expansion relative to faster-growing IT peers. The company's Rule of 40 metric, combining growth and profitability, would approximate 30.6% (6.0% growth + 24.6% EBITDA margin estimate), exceeding the industry median of 20% and indicating balanced performance. Asset turnover of 0.60 aligns closely with the industry median of 0.67, reflecting similar capital intensity in software-driven business models. Accounts receivable days of approximately 155 days significantly exceed the industry median of 61 days, representing an area for improvement in working capital management relative to sector peers.
(Industry: IT and Telecom, Comparison: FY2025 Q3, Source: Proprietary analysis)
The company demonstrates exceptional profitability characteristics with operating margin of 22.6% and ROE of 21.7% that place it in the top tier of healthcare IT solution providers, driven by a high-margin software and service business model with 57.0% gross margins. This structural profitability advantage has enabled accelerated earnings growth of 36.9% significantly outpacing revenue growth of 6.0%, reflecting operating leverage from the scalable platform. The balance sheet transformation is notable, with cash increasing 59.2% to ¥33.5B while maintaining conservative leverage at 0.19 debt-to-equity, providing substantial financial flexibility for strategic initiatives including the ¥8.0B in new long-term borrowings that appear designated for growth investments. Capital allocation shows balanced approach with conservative 15.2% dividend payout ratio supplemented by meaningful share repurchases evident in the ¥4.3B treasury stock increase, retaining majority earnings for reinvestment in the ¥46.3B intangible asset base that represents the company's competitive moat. The working capital profile warrants attention with 155-day receivable collection cycles double the industry median of 61 days, though strong cash generation has absorbed this thus far. Full-year guidance implies conservative positioning with 82-84% progress rates through Q3, suggesting potential for upside revision or robust Q4 buffer, though the temporary tax benefit of approximately ¥1.4B boosting FY2026 net income may not recur. The single-segment focus on pharmacy and healthcare solutions provides clear strategic focus but concentrates exposure to Japanese healthcare sector dynamics and regulatory evolution.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.